Nasolacrimal duct closure modulates ocular mucosal and systemic CD4 + T-cell responses induced following topical ocular or intranasal immunization

Clinical and Vaccine Immunology

Volumn 17, Issue 3, 2010, Pages 342-353

  Chentoufi, Aziz Alami ^a   Dasgupta, Gargi ^a   Nesburn, Anthony B ^a   Bettahi, Ilham ^a   Binder, Nicholas R ^a   Choudhury, Zareen S ^a   Chamberlain, Winston D ^a   Wechsler, Steven L ^a,b   Benmohamed, Lbachir ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN D; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CONJUNCTIVA; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; HERPES SIMPLEX VIRUS 1; IMMUNE SYSTEM; IMMUNIZATION; LACRIMAL DUCT; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; NONHUMAN; NOSE; NOSE CAVITY; PRIORITY JOURNAL; RABBIT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, TOPICAL; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; EPITOPES, T-LYMPHOCYTE; EYE; FLOW CYTOMETRY; HERPESVIRUS 1, HUMAN; IMMUNITY, MUCOSAL; IMMUNOHISTOCHEMISTRY; LYMPHOID TISSUE; MOLECULAR SEQUENCE DATA; NASAL CAVITY; NASOLACRIMAL DUCT; RABBITS; SPLEEN; VACCINATION; VACCINES;

EID: 77649240395     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00347-09     Document Type: Article

References (51)

1. BenMohamed, L., Y. Belkaid, E. Loing, K. Brahimi, H. Gras-Masse, and P. Druilhe. 2002. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32:2274-2281.
2. BenMohamed, L., G. Bertrand, C. D. McNamara, H. Gras-Masse, J. Hammer, S. L. Wechsler, and A. B. Nesburn. 2003. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77:9463-9473.
3. BenMohamed, L., R. Krishnan, C. Auge, J. F. Primus, and D. J. Diamond. 2002. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106:113-121.
4. BenMohamed, L., S. L. Wechsler, and A. B. Nesburn. 2002. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2:425-431.
5. Bettahi, I., A. B. Nesburn, S. Yoon, X. Zhang, A. Mohebbi, V. Sue, A. Vanderberg, S. L. Wechsler, and L. BenMohamed. 2007. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest. Ophthalmol. Vis. Sci. 48:4643-4653.
6. Bouchard, C. S., J. B. Lasky, J. E. Cundiff, and B. S. Smith. 1996. Ocular surface upregulation of intercellular adhesive molecule-1 (ICAM-1) by local interferon-gamma (IFN-gamma) in the rat. Curr. Eye Res. 15:203-208.
7. Boyaka, P. N., M. Marinaro, J. L. Vancott, I. Takahashi, K. Fujihashi, M. Yamamoto, F. W. van Ginkel, R. J. Jackson, H. Kiyono, and J. R. McGhee. 1999. Strategies for mucosal vaccine development. Am. J. Trop. Med. Hyg. 60:35-45.
8. Boyaka, P. N., A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170:5636-5643.
9. Chentoufi, A. A., X. Zhang, K. Lamberth, G. Dasgupta, I. Bettahi, A. Nguyen, M. Wu, X. Zhu, A. Mohebbi, S. Buus, S. L. Wechsler, A. B. Nesburn, and L. BenMohamed. 2008. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 180:426-437.
10. Dasgupta, G., A. A. Chentoufi, A. B. Nesburn, S. L. Wechsler, and L. BenMohamed. 2009. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev. Vaccines 8:1023-1035.
11. Dasgupta, G., A. B. Nesburn, S. L. Wechsler, and L. Benmohamed. 2010. Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiol. 5:1-4.
12. Dietrich, G., M. Griot-Wenk, I. C. Metcalfe, A. B. Lang, and J. F. Viret. 2003. Experience with registered mucosal vaccines. Vaccine 21:678-683.
13. Douce, G., M. M. Giuliani, V. Giannelli, M. G. Pizza, R. Rappuoli, and G. Dougan. 1998. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16:1065-1073.
14. Ellison, G. L., J. L. Warren, K. B. Knopf, and M. L. Brown. 2003. Racial differences in the receipt of bowel surveillance following potentially curative colorectal cancer surgery. Health Serv. Res. 38:1885-1903.
15. Goel, N., Q. Rong, D. Zimmerman, and K. S. Rosenthal. 2003. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine 21:4410-4420.
16. Harandi, A. M., K. Eriksson, and J. Holmgren. 2003. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J. Virol. 77:953-962.
17. Harandi, A. M., J. Sanchez, K. Eriksson, and J. Holmgren. 2003. Recent developments in mucosal immunomodulatory adjuvants. Curr. Opin. Invest. Drugs 4:156-161.
18. Hawkins, E. D., M. Hommel, M. L. Turner, F. L. Battye, J. F. Markham, and P. D. Hodgkin. 2007. Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data. Nat. Protoc. 2:2057-2067.
19. Holmgren, J., C. Czerkinsky, K. Eriksson, and A. Mharandi. 2003. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21(Suppl 2):S89-S95.
20. Knop, E., and N. Knop. 2003. Eye-associated lymphoid tissue (EALT) is continuously spread throughout the ocular surface from the lacrimal gland to the lacrimal drainage system. Ophthalmologe 100:929-942. (In German.)
21. Knop, E., and N. Knop. 2001. Lacrimal drainage-associated lymphoid tissue (LDALT): a part of the human mucosal immune system. Invest. Ophthalmol. Vis. Sci. 42:566-574.
22. Knop, E., and N. Knop. 2005. The role of eye-associated lymphoid tissue in corneal immune protection. J. Anat. 206:271-285.
23. Knop, E., N. Knop, and H. Brewitt. 2003. Dry eye disease as a complex dysregulation of the functional anatomy of the ocular surface. New concepts for understanding dry eye disease. Ophthalmologe 100:917-928. (In German.)
24. Knop, N., and E. Knop. 2005. Ultrastructural anatomy of CALT follicles in the rabbit reveals characteristics of M-cells, germinal centres and high endothelial venules. J. Anat. 207:409-426.
25. Kuper, C. F., P. J. Koornstra, D. M. Hameleers, J. Biewenga, B. J. Spit, A. M. Duijvestijn, P. J. van Breda Vriesman, and T. Sminia. 1992. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13:219-224.
26. Lenert, P., W. Rasmussen, R. F. Ashman, and Z. K. Ballas. 2003. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol. 22:621-631.
27. Manickan, E., M. Francotte, N. Kuklin, M. Dewerchin, C. Molitor, D. Gheysen, M. Slaoui, and B. T. Rouse. 1995. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J. Virol. 69:4711-4716.
28. Manickan, E., Z. Yu, R. J. Rouse, W. S. Wire, and B. T. Rouse. 1995. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27. Viral Immunol. 8:53-61.
29. Mbawuike, I., Y. Zang, and R. B. Couch. 2007. Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine 25:3263-3269.
30. McCluskie, M. J., and H. L. Davis. 1998. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161:4463- 4466.
31. Morrison, L. A., X. J. Da Costa, and D. M. Knipe. 1998. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 243: 178-187.
32. Mott, K. R., C. J. Bresee, S. J. Allen, L. BenMohamed, S. L. Wechsler, and H. Ghiasi. 2009. Level of herpes simplex virus type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice. J. Virol. 83:2246-2254.
33. Mott, K. R., A. A. Chentoufi, D. Carpenter, L. BenMohamed, S. Wechsler, and H. Ghiasi. 2009. The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on ocular virus replication and pathogenicity. Invest. Ophthalmol. Vis. Sci. 50:2903-2912.
34. Mutwiri, G., R. Pontarollo, S. Babiuk, P. Griebel, S. van Drunen Littel-van den Hurk, A. Mena, C. Tsang, V. Alcon, A. Nichani, X. Ioannou, S. Gomis, H. Townsend, R. Hecker, A. Potter, and L. A. Babiuk. 2003. Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet. Immunol. Immunopathol. 91:89-103.
35. Nesburn, A. B., I. Bettahi, G. Dasgupta, A. A. Chentoufi, X. Zhang, S. You, N. Morishige, A. J. Wahlert, D. J. Brown, J. V. Jester, S. L. Wechsler, and L. BenMohamed. 2007. Functional Foxp3+ CD4+ CD25(Bright+) "natural" regulatory T cells are abundant in rabbit conjunctiva and suppress virusspecific CD4+ and CD8+ effector T cells during ocular herpes infection. J. Virol. 81:7647-7661.
36. Nesburn, A. B., I. Bettahi, X. Zhang, X. Zhu, W. Chamberlain, R. E. Afifi, S. L. Wechsler, and L. BenMohamed. 2006. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4:178-187.
37. Nesburn, A. B., R. L. Burke, H. Ghiasi, S. M. Slanina, and S. L. Wechsler. 1998. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest. Ophthalmol. Vis. Sci. 39:1163-1170.
38. Nesburn, A. B., R. L. Burke, H. Ghiasi, S. M. Slanina, and S. L. Wechsler. 1998. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology 252: 200-209.
39. Nesburn, A. B., T. V. Ramos, X. Zhu, H. Asgarzadeh, V. Nguyen, and L. BenMohamed. 2005. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 23:873-883.
40. Nesburn, A. B., S. Slanina, R. L. Burke, H. Ghiasi, S. Bahri, and S. L. Wechsler. 1998. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J. Virol. 72:7715-7721.
41. Nochi, T., and H. Kiyono. 2006. Innate immunity in the mucosal immune system. Curr. Pharm. Des. 12:4203-4213.
42. Pyles, R. B., D. Higgins, C. Chalk, A. Zalar, J. Eiden, C. Brown, G. Van Nest, and L. R. Stanberry. 2002. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J. Virol. 76:11387-11396.
43. Richards, C. M., R. Case, T. R. Hirst, T. J. Hill, and N. A. Williams. 2003. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. J. Virol. 77:6692-6699.
44. Schlamp, C. L., A. T. Thliveris, Y. Li, L. P. Kohl, C. Knop, J. A. Dietz, I. V. Larsen, P. Imesch, L. H. Pinto, and R. W. Nickells. 2004. Insertion of the beta Geo promoter trap into the Fem1c gene of ROSA3 mice. Mol. Cell. Biol. 24:3794-3803.
45. Shukla, D., M. C. Dal Canto, C. L. Rowe, and P. G. Spear. 2000. Striking similarity of murine nectin-1alpha to human nectin-1alpha (HveC) in sequence and activity as a glycoprotein D receptor for alphaherpesvirus entry. J. Virol. 74:11773-11781.
46. Sundstedt, A., E. J. O'Neill, K. S. Nicolson, and D. C. Wraith. 2003. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J. Immunol. 170:1240-1248.
47. Takabayashi, K., L. Libet, D. Chisholm, J. Zubeldia, and A. A. Horner. 2003. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J. Immunol. 170:3898-3905.
48. Takahashi, I., T. Nochi, Y. Yuki, and H. Kiyono. 2009. New horizon of mucosal immunity and vaccines. Curr. Opin. Immunol. 21:352-358.
49. Yamamoto, M., D. E. Briles, S. Yamamoto, M. Ohmura, H. Kiyono, and J. R. McGhee. 1998. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161:4115-4121.
50. Yuki, Y., and H. Kiyono. 2009. Mucosal vaccines: novel advances in technology and delivery. Expert Rev. Vaccines 8:1083-1097.
51. Zhang, X., A. A. Chentoufi, G. Dasgupta, A. B. Nesburn, M. Wu, X. Zhu, D. Carpenter, S. L. Wechsler, S. You, and L. BenMohamed. 2009. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2:129-143.